Conference Reports for NATAP

Back

26th Conference of the Asian Pacific Association for the Study of the Liver 2017 APASL, Feb 15-19 Shanghai, China     Safety and Efficacy of Nivolumab in Patients With Advanced Hepatocellular Carcinoma: Interim Analysis of the Phase 1/2 CheckMate 040 Study - (04/04/17)   Improvement in Fibrosis Parameters Following Treatment With Fixed-Dose Daclatasvir/Asunaprevir/Beclabuvir in Japanese Patients With Chronic HCV GT 1 Infection - (03/22/17)   Correlation of Early Biochemical and Virologic Responses During Oral Antiviral Therapy for Chronic Hepatitis B - (03/16/17)   Characterization of Host, Viral, and Treatment-Related Factors Associated With Antiviral Efficacy of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate - (03/16/17)   HBV Genotype Is Associated With Early (Week 12) Virologic Response During Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Therapy in Patients With Chronic Hepatitis B - (03/16/17)   C-EDGE CO-STAR: Interim Results From the 3-year Follow-up Trial on Risk Factors and Rate of Reinfection in Patients on Opiate Agonist Therapy Previously Treated With Elbasvir/Grazoprevir for 12 Week - (03/15/17)   Reduced Changes in Bone Mineral Density in Chronic HBV Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (03/15/17)   Improved Renal Laboratory Parameters in Chronic HBV (CHB) Patients Treated With Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) - (03/15/17)   HIGH EFFICACY IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1b INFECTION TREATED WITH ELBASVIR/GRAZOPREVIR FOR 12 WEEKS: AN INTEGRATED ANALYSIS - (03/15/17)   EFFICACY AND SAFETY OF ELBASVIR/GRAZOPREVIR IN TREATMENT-NAïVE PATIENTS WITH CHRONIC HCV GT 1, GT 4 AND GT 6 INFECTION (C-CORAL): A PHASE III RANDOMIZED MULTINATIONAL CLINICAL TRIAL - (03/15/17)   Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients With Mild or Moderate Renal Impairment - (03/15/17)   A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF), with or without Ribavirin (RBV), in HCV Infected Subjects Who Have Failed Prior Treatment with Non-NS5A, SOF-based Therapies (RESCUE) - (03/15/17)   Sofosbuvir/Velpatasvir for 12 Weeks Results in High SVR12 Rates with a Favorable Safety Profile in Asian Patients: an Integrated Subgroup Analysis of From the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies - (03/15/17)   Prevalence of Pretreatment NS5A and NS5B NI-Resistance Associated Substitutions in HCV-Infected Patients Enrolled in Clinical Trials in Asia - (03/15/17)   Ledipasvir/Sofosbuvir in Egyptian Patients With Chronic Genotype 4 HCV Infection - (03/15/17)   Long-term Follow-up of Patients With Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment With Sofosbuvir-Based Regimens - (03/15/17)   Ledipasvir/Sofosbuvir in Patients with Chronic HCV and HIV/HCV Coinfection and in SOF-Experienced Patients - (03/15/17)   Impact of a 12-Week Oral Regimen of Elbasvir/Grazoprevir (EBR/GZR) On Health-Related Quality of Life (HRQOL) and Fatigue in Treatment-Naïve Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 4, or 6 Infection: Data From the C-CORAL Study - (03/15/17)   Elbasvir/Grazoprevir + Sofosbuvir ± Ribavirin in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: The C-ISLE Study - (03/15/17)   Prevention of Liver-Related Complications in Patients With Chronic Hepatitis C Receiving Elbasvir/Grazoprevir Compared With Pegylated Interferon/Ribavirin andNo Treatment in Vietnam - (03/15/17)   ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection - A Randomized, Double-Blind, Placebo-Controlled Study - (03/14/17)   GARNET: High SVR Rates Following 8-Week Treatment With Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir in Patients With HCV Genotype 1b Infection - (03/14/17)   Safety, Efficacy, and Clinical Outcomes in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in the TOPAZ-I and TOPAZ-II Trials - (03/13/17)   Long-Term Evaluation of Liver Stiffness and Blood Markers in Hepatiti s C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin: Interim Results from TOPAZ-I and TOPAZ-II - from Jules: TREAT EARLY - (03/13/17)   Elbasvir/Grazoprevir Does Not Worsen Renal Function in Patients With Hepatitis C Virus Infection and Pre-existing Renal Disease - (03/08/17)   Clinical Pharmacokinetics and Antiviral Activity of CC-31244, a Pan-genotypic, Potent Nonnucleoside NS5B Polymerase Inhibitor (NNI) for the Treatment of Hepatitis C - (02/21/17)   Sofosbuvir-Containing Regimens Are Safe and Effective in Adolescents With Chronic Hepatitis C Infection - (02/21/17)   Sofosbuvir/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study - (02/21/17)   ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis - (02/21/17)   PROJECTED IMPACT OF ELBASVIR/GRAZOPREVIR IN TREATMENT-NAÏVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 AND CHRONIC KIDNEY DISEASE IN VIETNAM - (02/21/17)   Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (02/21/17)   Clinical Pharmacokinetics and Antiviral Activity of CC-31244, a Pan-genotypic, Potent Nonnucleoside NS5B Polymerase Inhibitor (NNI) for the Treatment of Hepatitis C - (02/21/17)